TEVA-TOPISONE CREAM

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE)

זמין מ:

TEVA CANADA LIMITED

קוד ATC:

D07AC01

INN (שם בינלאומי):

BETAMETHASONE

כמות:

0.05%

טופס פרצבטיות:

CREAM

הרכב:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%

מסלול נתינה (של תרופות):

TOPICAL

יחידות באריזה:

15/50/450G

סוג מרשם:

Prescription

איזור תרפויטי:

ANTI-INFLAMMATORY AGENTS

leaflet_short:

Active ingredient group (AIG) number: 0106299002; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2002-03-08

מאפייני מוצר

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-TOPISONE
BETAMETHASONE DIPROPIONATE
USP
0.05% W/W BETAMETHASONE (AS DIPROPIONATE) CREAM, OINTMENT AND LOTION
TOPICAL CORTICOSTEROID
TEVA CANADA LIMITED
DATE OF REVISION
30 NOVOPHARM COURT
FEB.24, 2021
TORONTO, ONTARIO
CANADA M1B 2K9
WWW.TEVACANADA.COM
CONTROL #: 245679
Page 2
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
1.
INDICATIONS
......................................................................................................
3
1.1 PEDIATRICS
.........................................................................................................
3
1.2 GERIATRICS
.........................................................................................................
3
2.
CONTRAINDICATIONS
........................................................................................
4
3.
DOSAGE AND ADMINISTRATION
......................................................................
4
3.1 DOSING CONSIDERATIONS
....................................................................................
4
3.2 ADMINISTRATION
..................................................................................................
4
4.
MISSED DOSE
.....................................................................................................
4
5.
OVERDOSAGE
.....................................................................................................
5
6.
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............. 5
7.
WARNINGS AND PRECAUTIONS
.......................................................................
6
7.1 SPECIAL POPULATIONS
.........................................................................................
7
7.1.1 PREGNANT WOMEN
...........................................................................................
7
7.1.2 BREAST-FEEDING
...............................................................................................
7
7.1.3 PEDIATRICS
.